Clinical Trials Logo

Filter by:
NCT ID: NCT01515189 Completed - Melanoma Clinical Trials

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Start date: February 17, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg

NCT ID: NCT01512979 Completed - Clinical trials for Diabetes Mellitus, Type 2

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Start date: January 2012
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.

NCT ID: NCT01512368 Completed - Sedentary Lifestyle Clinical Trials

Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels Correlated With Exercise

Start date: March 2010
Phase: N/A
Study type: Interventional

We evaluated the effect of two weeks of intensive supervised physical activity in serum fibroblast growth factor 21 (FGF21) levels.

NCT ID: NCT01507831 Completed - Clinical trials for Hypercholesterolemia

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Start date: January 2012
Phase: Phase 3
Study type: Interventional

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Primary Objective of the study: To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT). Secondary Objectives: - To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo. - To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points. - To evaluate the effects of alirocumab on other lipid parameters.

NCT ID: NCT01507116 Completed - Clinical trials for Diabetes Mellitus, Type 2

Diabetes Attitudes Wishes and Needs

DAWN2
Start date: March 2012
Phase: N/A
Study type: Observational

The study is conducted in Africa, Asia, Europe, Japan, North America and South America. The multinational surveys will explore the experiences and unmet needs of people with diabetes, as well as those of family members of people with diabetes, and of healthcare professionals treating people with diabetes.

NCT ID: NCT01506258 Recruiting - Clinical trials for Multiple Organ Failure

Autologous Stem Cells in Newborns With Oxygen Deprivation

Start date: January 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the plasticity of autologous intravenous application of cord blood stem cells would improve the clinical course of asphyxiated newborns.

NCT ID: NCT01505023 Completed - Obesity Clinical Trials

Partial Meal Replacement and Inulin in Obese Women

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The objective of this study was to test the efficacy of a partial meal replacement added with vitamins, minerals and inulin on weight reduction, blood lipids and micronutrients intake in obese Mexican women

NCT ID: NCT01504594 Suspended - Clinical trials for Cardiomyopathy, Dilated

Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether an autologous stem cell infusion through catheterism is safe and effective in the treatment of pediatric dilated cardiomyopathy. Process: 1. Primary Evaluation - Clinical History - Echocardiogram to evaluate ejection fraction and other parameters 2. Signing of Informed Consent and clearing doubts 3. Bone Marrow stimulation for 3 consecutive days with G-CSF (Granulocyte Colony Stimulating Factor) applied subcutaneously 4. On the 4th day, in operation room and under sedation: Bone Marrow Harvest performed by hematologists through posterior iliac crests(amount calculated at 8cc/kg, without exceeding 150ml). 5. Recovery room with family members while the cells are being processed in the Hematology Laboratory. 6. Approximately 3 hours after the 1st procedure, the patient re-enters the operation room, which is equipped for cardiac catheterization, so that cardiologists infuse the stem cells through the femoral artery into the coronary arteries which irrigate the heart´s muscle fibers. 7. Patient goes back to the recovery area until the anesthesia effect is gone and can tolerate oral liquids. 8. Clinical and echocardiographic follow-ups at 6 weeks and 6 months after the procedure.

NCT ID: NCT01503970 Completed - Clinical trials for Tear; Knee, Cartilage, Articular

Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration

Start date: December 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess safety and efficacy of autologous chondrocyte implantation delivered arthroscopically into chondral lesions of the knee using clinical, biochemical, and MRI outcomes.

NCT ID: NCT01502514 Withdrawn - Clinical trials for Ischemic Congestive Heart Failure

Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure

Start date: May 2011
Phase: Phase 1
Study type: Interventional

The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements indicating improvement, stability, or degradation of a patient's cardiovascular function and exercise capacity?